The word TRETHERA in bold, modern font with horizontal orange bars incorporated into the letters E and H on a light background.The word TRETHERA in bold, modern font with horizontal orange bars incorporated into the letters E and H on a light background.White text TRETHERA on a light gray background, with orange horizontal bars inside the letters E and H. The design is modern and minimalistic.

Behind every indication is a person

Trethera is developing TRE-515 for people facing cancer, autoimmune disease, and ALS, and for their families beside them. This is why we do the work.

Our Commitment

Precision, with people at the center.

TRE-515 was designed to target disease driving cells, with the goal of sparing patients the harsh toll of conventional treatments.

Designed for precision

A selective dCK inhibitor designed to exploit a metabolic vulnerability associated with disease.

Quality of life matters

Reducing the treatment burden is part of the goal, not an afterthought. A pill is easier than an infusion appointment.

Following the evidence

Every indication we pursue follows the science toward the people who need it most.

Our Commitment

Precision, with people at the center.

TRE-515 was designed to target disease driving cells, with the goal of sparing patients the harsh toll of conventional treatments.

Designed for precision

A selective dCK inhibitor designed to exploit a metabolic vulnerability associated with disease.

Quality of life matters

Reducing the treatment burden is part of the goal, not an afterthought. A pill is easier than an infusion appointment.

Following the evidence

Every indication we pursue follows the science toward the people who need it most.

Patient Stories

The people we work for.

Shared with permission, in the words of patients and families who have lived it.

Oncology

Stephanie’s story

Stephanie was the first person ever to receive TRE-515. She joined the Phase 1 trial when there was no patient experience with the drug to go on, and she openly shared what the months on treatment have actually been like.

“There are even days that I forget I have cancer.”

Stephanie, first patient to receive TRE-515

* Individual experiences do not establish safety or efficacy
ALS

Frank’s story

An ALS patient who received TRE-515 through the FDA Expanded Access pathway, shared with his family’s blessing.

“I think that TRE-515 changed my attitude. I’m hopeful.”

Frank, first ALS patient to receive TRE-515

* Individual experiences do not establish safety or efficacy
Expanded access

Information on Expanded Access to TRE-515.

Expanded access, sometimes called compassionate use, is a potential pathway for a patient with a serious condition to request an investigational therapy outside of a clinical trial, when they may not be eligible for a trial, and no comparable option is available.

Whether it is appropriate is a decision to make with your physician. If you or your physician would like information about expanded access to TRE-515, you can reach us at the address below. We are obliged to provide a way to make this request, and we review each inquiry individually.

Read the Expanded Access Policy
This information is provided for awareness. It is not medical advice and not a promise of access.
Expanded access

Information on Expanded Access to TRE-515.

Expanded access, sometimes called compassionate use, is a potential pathway for a patient with a serious condition to request an investigational therapy outside of a clinical trial, when they may not be eligible for a trial, and no comparable option is available.

Whether it is appropriate is a decision to make with your physician. If you or your physician would like information about expanded access to TRE-515, you can reach us at the address below. We are obliged to provide a way to make this request, and we review each inquiry individually.

Read the Expanded Access Policy
This information is provided for awareness. It is not medical advice and not a promise of access.